GlassScriptPhysician profile
Minji Kim
NPI 1720424591
$28,404.27
in general payments reported to CMS, 2019-2025
23 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $75.68 · 2021: $255 · 2022: $749 · 2023: $1,068 · 2024: $6,070 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $6,709 · Food and Beverage: $2,486 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,300.00 |
| Travel and Lodging | $6,709.39 |
| Food and Beverage | $2,485.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $687.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $13,649.15 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $9,940.36 | 2025 | Uplizna |
| Boston Scientific Corporation | $1,778.64 | 2019-2023 | Vercise |
| Livanova USA, INC. | $965.51 | 2019 | |
| Medtronic USA, INC. | $400.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $250.97 | 2025 | Wainua |
| Becton, Dickinson and Company | $199.68 | 2025 | Phasix Mesh |
| Alexion Pharmaceuticals, INC. | $179.34 | 2022 | |
| Allergan, INC. | $157.00 | 2019-2022 | |
| Abbvie INC. | $126.05 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $102.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $99.97 | 2021 | |
| Genentech USA, INC. | $98.94 | 2025 | Ocrevus |
| Biogen, INC. | $98.68 | 2022 | |
| Sk Life Science, INC. | $87.25 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $70.32 | 2021 | |
| Cadwell Industries, INC | $70.00 | 2025 | |
| Upsher-Smith Laboratories LLC | $39.06 | 2020 | |
| Ucb, INC. | $25.46 | 2025 | Rystiggo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.94 | 2025 | Hyqvia |
| Genzyme Corporation | $19.35 | 2022 | |
| Acorda Therapeutics, INC | $13.56 | 2020 | |
| Biomarin Pharmaceutical INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minji Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.